

For Immediate Release

TSX Exchange Symbol: RVX

Resverlogix to Present at Prestigious DALM Scientific Conference*RVX-208 novel Apo A-I/HDL drug featured in oral presentation in New York*

Calgary, AB July 20, 2007 – Resverlogix Corp. (“Resverlogix”) (TSX:RVX) is pleased to announce today that the company has been notified that its abstract submission has been accepted. Resverlogix will do an oral presentation on key scientific data of its lead molecule RVX-208 at the 16th International Symposium for Drugs Affecting Lipid Metabolism (DALM). The presentation titled, “A novel drug RVX-208 raises plasma apolipoprotein A-I and HDL cholesterol,” will be presented by Dr. Norman Wong, Resverlogix co-founder and chairman of the scientific advisory board on the opening day of the conference, October 4, 2007, in New York City.

“This conference is an international venue for the presentation of state of the art current therapeutics and research for the prevention of atherosclerosis and other cardiovascular diseases. We are pleased to present data of Resverlogix’s novel small molecule RVX-208 which enhances the production of ApoA-I and HDL. A growing body of evidence from predictive animal models, including non-human primates, indicates RVX-208’s potential for preventing or regressing atherosclerosis, this data will be included in this important scientific conference,” stated Dr Jan Johansson, Senior Vice President of Clinical Affairs of Resverlogix. Dr. Johansson added, “It is well endorsed by the scientific community that a small molecule that increases ApoA-I production, represents the holy grail for atherosclerosis protection.”

Mr. Donald McCaffrey, co-founder and CEO of Resverlogix said, “There is a large unmet medical need that this novel, first in class molecule could address. As RVX-208 quickly approaches the submission for an Investigational New Drug and clinical testing the interest for RVX-208 accelerates on many fronts. A permanent increase in ApoA-I and HDL production has the potential to eliminate atherosclerosis and make a significant impact on how many cardiovascular diseases are treated. Due to the overwhelming scientific data that we have generated, our international peers have expressed great interest in our lead candidate, RVX-208. We look forward to announcing additional peer reviewed presentations in the near future.”

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas™ program is the Company’s primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer’s and other vascular disorders. The Company’s secondary focus is TGF-Beta Shield™, a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

For further information please contact:

Theresa Kennedy
VP, Corporate Communications
Resverlogix Corp.
Phone: 604-538-7072
Fax: 403-256-8495
Email: Theresa@resverlogix.com

Kenneth Lebioda
SVP, Business & Market Development
Resverlogix Corp.
Phone: 403-254-9252
Fax: 403-256-8495
Email: Ken@resverlogix.com

Website: www.resverlogix.com